Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin and heart disease

This article was originally published in The Tan Sheet

Executive Summary

Cardiovascular benefits of aspirin as primary prevention for coronary heart disease outweigh risks of bleeding, but not in all cases, meta-analysis of four clinical trials published in March issue of Heart concludes. "Aspirin treatment for primary prevention is safe and worthwhile at coronary event risk >/= 1.5%/year," P. S. Sanmuganathan, Royal Hallamshire Hospital, Sheffield, England, et al., say, noting "limited value" at 1% per year and unsafe risk at .5%/year. Researchers stress "formal accurate estimation of absolute coronary risk" must be conducted before therapy begins
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel